Evidence map›Paper›PMID 38951492›Full record

ArticleNature communications2024

HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages.

Maria C Virgilio, Barkha Ramnani, Thomas Chen, W Miguel Disbennett, Jay Lubow, Joshua D Welch, Kathleen L Collins

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Manipulation of the cell cycle by HIV-1.Biochemical Society transactions · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Advances in Single-Cell Sequencing for Infectious Diseases: Progress and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Maria C VirgilioCellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-4940-188X
Barkha RamnaniDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0009-1040-9612
Thomas ChenDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
W Miguel DisbennettDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
Jay LubowDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
Joshua D WelchDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-5869-2391
Kathleen L CollinsCellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI, USA. klcollin@umich.edu.ORCID 0000-0002-1712-5809

Funding

CELLULAR AND MOLECULAR BIOLOGY AT MICHIGANT32GM007315 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PUTHENVEEDU, MANOJKUMAR A · 1985 to 2021
$12.8M
Cellular Biotechnology Training Program (CBTP)T32GM008353 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHWENDEMAN, ANNA · 1991 to 2021
$9.3M
University of Michigan Postbaccalaureate Research Education Program (UM PREP)R25GM086262 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALLEN, BENJAMIN · 2009 to 2024
$6.1M
Integrative Single-Cell Analysis of Transcriptome, Epigenome, and Lineage in HIV Latency and ActivationR01AI149669 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L., WELCH, JOSHUA · 2020 to 2024
$3.4M
Single-cell multi-omic analysis of opioid-mediated HIV disease pathogenesisR61DA059916 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L., WELCH, JOSHUA · 2023 to 2024
$1.0M
HIV evasion of the innate immune responseR21AI132379 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 2018 to 2019
$415k
Investigating the Role of Innate Immune Factors in Restricting HIV Spread in MacrophagesF31AI125090 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBOW, DAVID JAY · 2016 to 2016
$35k
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) F31AI125090-01Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) F31AI15504Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI149669Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R21AI32379NIAID NIH HHS F31 AI125090NIAID NIH HHS R01 AI149669NIAID NIH HHS R21 AI132379NIDA NIH HHS R61 DA059916NIGMS NIH HHS R25 GM086262NIGMS NIH HHS T32 GM007315NIGMS NIH HHS T32 GM008353U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) 5T32GM008353-27U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007315U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) 1R61DA059916-01
6 · The paper itself

Abstract

HIV-1 Vpr promotes efficient spread of HIV-1 from macrophages to T cells by transcriptionally downmodulating restriction factors that target HIV-1 Envelope protein (Env). Here we find that Vpr induces broad transcriptomic changes by targeting PU.1, a transcription factor necessary for expression of host innate immune response genes, including those that target Env. Consistent with this, we find silencing PU.1 in infected macrophages lacking Vpr rescues Env. Vpr downmodulates PU.1 through a proteasomal degradation pathway that depends on physical interactions with PU.1 and DCAF1, a component of the Cul4A E3 ubiquitin ligase. The capacity for Vpr to target PU.1 is highly conserved across primate lentiviruses. In addition to impacting infected cells, we find that Vpr suppresses expression of innate immune response genes in uninfected bystander cells, and that virion-associated Vpr can degrade PU.1. Together, we demonstrate Vpr counteracts PU.1 in macrophages to blunt antiviral immune responses and promote viral spread.

Indexed as

HIV-1Immunity, InnateMacrophagesProto-Oncogene ProteinsTrans-Activatorsvpr Gene Products, Human Immunodeficiency VirusHEK293 CellsHIV InfectionsHumansProtein Serine-Threonine KinasesProto-Oncogene Protein Spi-1Ubiquitin-Protein LigasesVirionDCAF1 protein, humanProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-ActivatorsUbiquitin-Protein Ligasesvpr Gene Products, Human Immunodeficiency Virusvpr protein, Human immunodeficiency virus 1

Identifiers

PMID38951492
PMCPMC11217462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.